Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 928-932

  McCarty, Mark F ^a  

^a Natural Alternatives International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GUANYLATE CYCLASE; TRANSCRIPTION FACTOR;

ARTICLE; CELL DIFFERENTIATION; CELL VOLUME; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DOWN REGULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

BIOTIN; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, PROTEIN-RESTRICTED; DRUG THERAPY, COMBINATION; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; PEPTIDES; VENOMS;

EID: 34547830908     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.09.059     Document Type: Article

References (64)

1. Leahy J.L., Bonner-Weir S., and Weir G.C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15 (1992) 442-455
2. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44 (1995) 863-870
3. Roduit R., Morin J., Masse F., Segall L., Roche E., Newgard C.B., et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta-cell. J Biol Chem 275 (2000) 35799-35806
4. McCarty M.F. Incorporation of beta cell redifferentiation therapy into a lipoprivic strategy for reversing type 2 diabetes. Med Hypotheses 58 (2002) 462-471
5. Gremlich S., Bonny C., Waeber G., and Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem 272 (1997) 30261-30269
6. Zangen D.H., Bonner-Weir S., Lee C.H., Latimer J.B., Miller C.P., Habener J.F., et al. Reduced insulin, GLUT2, and IDX-1 in beta-cells after partial pancreatectomy. Diabetes 46 (1997) 258-264
7. Weir G.C., Sharma A., Zangen D.H., and Bonner-Weir S. Transcription factor abnormalities as a cause of beta cell dysfunction in diabetes: a hypothesis. Acta Diabetol 34 (1997) 177-184
8. Watada H., Kajimoto Y., Miyagawa J., Hanafusa T., Hamaguchi K., Matsuoka T., et al. PDX-1 induces insulin and glucokinase gene expressions in alpha TC1 clone 6 cells in the presence of betacellulin. Diabetes 45 (1996) 1826-1831
9. Habener J.F., and Staffers D.A. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Assoc Am Physicians 110 (1998) 12-21
10. Yoshida S., Kajimoto Y., Yasuda T., Watada H., Fujitani Y., Kosaka H., et al. PDX-1 induces differentiation of intestinal epithelioid IEC-6 into insulin-producing cells. Diabetes 51 (2002) 2505-2513
11. Ashizawa S., Brunicardi F.C., and Wang X.P. PDX-1 and the pancreas. Pancreas 28 (2004) 109-120
12. Allen F.M. Prolonged fasting in diabetes. Am J Med Sci 159 (1915) 480-485
13. Fuhrman J. Fasting and eating for health (1995), St. Martin's Griffin, New York p. 138-142
14. Prentki M., My E., El Assaad W., and Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 51 Suppl 3 (2002) S405-S413
15. Robertson R.P., Harmon J., Tran P.O., and Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 Suppl 1 (2004) S119-S124
16. Hanefeld M., and Week M. Very low calorie diet therapy in obese non-insulin dependent diabetes patients. Int J Obes 13 Suppl 2 (1989) 33-37
17. Week M., Hanefeld M., and Schollberg K. Effects of VLCD in obese NIDDM (non-insulin dependent diabetes) on glucose, insulin and C-peptide dynamics. Int J Obes 13 Suppl 2 (1989) 159-160
18. Fukuda M., Tahara Y., Yamamoto Y., Onishi T., Kumahara Y., Tanaka A., et al. Effects of very-low-calorie diet weight reduction on glucose tolerance, insulin secretion, and insulin resistance in obese non-insulin-dependent diabetics. Diabetes Res Clin Pract 7 (1989) 61-67
19. Wing R.R., Marcus M.D., Salata R., Epstein L.H., Miaskiewicz S., and Blair E.H. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Int Med 151 (1991) 1334-1340
20. Henry R.R., and Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 14 (1991) 802-823
21. Wing R.R., Blair E.H., Bononi P., Marcus M.D., Watanabe R., and Bergman R.N. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17 (1994) 30-36
22. Capstick F., Brooks B.A., Burns C.M., Zilkens R.R., Steinbeck K.S., and Yue D.K. Very low calorie diet (VLCD): a useful alternative in the treatment of the obese NIDDM patient. Diabetes Res Clin Pract 36 (1997) 105-111
23. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88
24. Joy S.V., Rodgers P.T., and Scates A.C. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 39 (2005) 110-118
25. Holz G.G. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res 36 (2004) 787-794
26. Staffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000) 741-748
27. Zhou J., Pineyro M.A., Wang X., Doyle M.E., and Egan J.M. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. J Cell Physiol 192 (2002) 304-314
28. Movassat J., Beattie G.M., Lopez A.D., and Hayek A. Exendin-4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab 87 (2002) 4775-4781
29. Kodama S., Toyonaga T., Kondo T., Matsumoto K., Tsuruzoe K., Kawashima J., et al. Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice. Biochem Biophys Res Commun 327 (2005) 1170-1178
30. Wang X., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142 (2001) 1820-1827
31. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
32. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
33. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146 (2005) 2069-2076
34. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
35. Maedler K., and Donath M.Y. Beta-cells in type 2 diabetes: a loss of function and mass. Horm Res 62 Suppl 3 (2004) 67-73
36. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 5 (2005) 275-286
37. El Assaad W., Buteau J., Peyot M.L., Nolan C., Roduit R., Hardy S., et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144 (2003) 4154-4163
38. Maedler K., Spinas G.A., Lehmann R., Sergeev P., Weber M., Fontana A., et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50 (2001) 1683-1690
39. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47 (1998) 358-364
40. Buteau J., El Assaad W., Rhodes C.J., Rosenberg L., My E., and Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47 (2004) 806-815
41. Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., Reed J., et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 17 (2003) 1575-1580
42. Vesely D.L. Biotin enhances guanylate cyclase activity. Science 216 (1982) 1329-1330
43. Spence J.T., and Koudelka A.P. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. J Biol Chem 259 (1984) 6393-6396
44. Singh I.N., and Dakshinamurti K. Stimulation of guanylate cyclase and RNA polymerase II activities in HeLa cells and fibroblasts by biotin. Mol Cell Biochem 79 (1988) 47-55
45. Borboni P., Magnaterra R., Rabini R.A., Staffolani R., Porzio O., Sesti G., et al. Effect of biotin on glucokinase activity, mRNA expression and insulin release in cultured beta-cells. Acta Diabetol 33 (1996) 154-158
46. Romero-Navarro G., Cabrera-Valladares G., German M.S., Matschinsky F.M., Velazquez A., Wang J., et al. Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin-deficient rats. Endocrinology 140 (1999) 4595-4600
47. Furukawa Y. Enhancement of glucose-induced insulin secretion and modification of glucose metabolism by biotin. Nippon Rinsho 57 (1999) 2261-2269
48. Sone H., Ito M., Shimizu M., Sasaki Y., Komai M., and Furukawa Y. Characteristics of the biotin enhancement of glucose-induced insulin release in pancreatic islets of the rat. Biosci Biotechnol Biochem 64 (2000) 550-554
49. Yoshikawa H., Tajiri Y., Sako Y., Hashimoto T., Umeda F., and Nawata H. Effects of biotin on glucotoxicity or lipotoxicity in rat pancreatic islets. Metabolism 51 (2002) 163-168
50. 2+ concentration in rat pancreatic beta-cells. Life Sci 65 (1999) 1515-1522
51. 2+ concentration of rat pancreatic beta-cells. J Pharmacol Sci 91 (2003) 41-46
52. 2+ concentration and insulin secretion in rat pancreatic beta-cells. Am J Physiol Cell Physiol 284 (2003) C1215-C1222
53. Gunther L., Berberat P.O., Haga M., Brouard S., Smith R.N., Soares M.P., et al. Carbon monoxide protects pancreatic beta-cells from apoptosis and improves islet function/survival after transplantation. Diabetes 51 (2002) 994-999
54. Pilz R.B., and Casteel D.E. Regulation of gene expression by cyclic GMP. Circ Res 93 (2003) 1034-1046
55. Liu H., and Maurice D.H. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125 (1998) 1501-1510
56. Baez-Saldana A., Zendejas-Ruiz I., Revilla-Monsalve C., Islas-Andrade S., Cardenas A., Rojas-Ochoa A., et al. Effects of biotin on pyruvate carboxylase, acetyl-CoA carboxylase, propionyl-CoA carboxylase, and markers for glucose and lipid homeostasis in type 2 diabetic patients and nondiabetic subjects. Am J Clin Nutr 79 (2004) 238-243
57. Maebashi M., Makino Y., Furukawa Y., et al. Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin-dependent diabetes mellitus. J Clin Biochem Nutr 14 (1993) 211-218
58. Reddi A., DeAngelis B., Frank O., Lasker N., and Baker H. Biotin supplementation improves glucose and insulin tolerances in genetically diabetic KK mice. Life Sci 42 (1988) 1323-1330
59. Zhang H., Osada K., Maebashi M., Ito M., Komai M., and Furukawa Y. A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus. J Nutr Sci Vitaminol (Tokyo) 42 (1996) 517-526
60. Dakshinamurti K., and Li W. Transcriptional regulation of liver phosphoenolpyruvate carboxykinase by biotin in diabetic rats. Mol Cell Biochem 132 (1994) 127-132
61. McCarty M.F. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Med Hypotheses 52 (1999) 401-406
62. Mock D.M. Biotin. In: Ziegler E.E., and Filer Jr. L.J. (Eds). Present Knowledge in Nutrition. 7th ed. (1996), ILSI Press, Washington, DC 220-235
63. Stone J.R., and Marietta M.A. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 33 (1994) 5636-5640
64. Barnard R.J., Jung T., and Inkeles S.B. Diet and exercise in the treatment of NIDDM. The need for early emphasis. Diabetes Care 17 (1994) 1469-1472